DELRAY BEACH, Fla., Aug. 11, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (Nasdaq:PSID), a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced today that the Department of Homeland Security (“DHS”) Science and Technologies division has validated the performance of the Company’s recently launched Multiplex BioThreat Assay (“MBA”), the PSIDMBA, through an in-house blind study. This validation was performed under the direction of and funded by DHS S&T. The PSIDMBA, available at www.psidmba.com, is the first commercially available MBA for the detection of up to six bio-threat organisms on the Centers for Disease Control & Prevention (“CDC”) Category A and B lists. The PSIDMBA was developed and perfected over a five-year period by MicroFluidic Systems (“MFS”), the Company’s wholly owned subsidiary.
